Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study

References

• Dobesh PP. Managing hypertension in patients with Type 2 diabetes mellitus. Am. J. Health. Syst. Pharm.63(12), 1140–1149 (2006).
   PubMed Web of Science ®Google Scholar
• Medrano MJ, Cerrato E, Boix R, Delgado-Rodríguez M. Cardiovascular risk factors in Spanish population: metaanalysis of cross-sectional studies. Med. Clin. (Barc).124(16), 606–612 (2005).
   PubMed Web of Science ®Google Scholar
• de Pablos-Velasco PL, Martínez-Martín FJ, Molero R et al. Patterns of prescription of hypoglycaemic drugs in Gran Canaria (Canary Islands, Spain) and estimation of the prevalence of diabetes mellitus. Diabetes Metab.31(5), 457–462 (2005).
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A et al. Global prevalence of diabetes; estimates for the year 2000 and projections for 2030. Diabetes Care21(5), 1047–1053 (2004).
   Google Scholar
• Landsberg L, Molitch M. Diabetes and hypertension: pathogenesis, prevention and treatment. Clin. Exp. Hypertens.26(7–8), 621–628 (2004).
   PubMed Web of Science ®Google Scholar
• Stratton IM, Cull CA, Adler AI et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in Type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia49(8), 1761–1769 (2006).
   PubMed Web of Science ®Google Scholar
• European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. [Errata in J. Hypertens.21, 2203–2204 (2003) and J. Hypertens.22, 435 (2004)] J. Hypertens.21(6), 1011–1053 (2003).
   Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA289(19), 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A et al. 2007 guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). [Erratum in J. Hypertens.25, 1749 (2007)] J. Hypertens.25 (9), 1105–1187 (2007).
   Google Scholar
• Turnbull F; Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
   PubMed Web of Science ®Google Scholar
• Franklin SS, Neutel JM. Initial combination therapy for rapid and effective control of moderate and severe hypertension. J. Hum. Hypertens. DOI:10.1038/jhh.2008.72 (Epub ahead of print) (2008).
   Google Scholar
• McLean DL, Simpson SH, McAlister FA, Tsuyuki RT. Treatment and blood pressure control in 47,964 people with diabetes and hypertension: a systematic review of observational studies. Can. J. Cardiol.22(10), 855–860 (2006).
   PubMed Web of Science ®Google Scholar
• Banegas JR, Segura J, Ruilope LM et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension43(6), 1338–1344 (2004).
   PubMed Web of Science ®Google Scholar
• Weir MR. Microalbuminuria in Type 2 diabetics: an important, overlooked cardiovascular risk factor. J. Clin. Hypertens.6(3), 134–141 (2004).
   PubMedGoogle Scholar
• Tobe SW, McFarlane PA, Naimark DM. Microalbuminuria in diabetes mellitus. Can. Med. Assoc. J.167(5), 499–503 (2002).
   PubMed Web of Science ®Google Scholar
• Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs65(Suppl. 2), 1–10 (2005).
   PubMed Web of Science ®Google Scholar
• Hirakata H, Iino K, Ishida I et al. Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus. Blood Press. Suppl.3, 124–129 (1992).
   PubMedGoogle Scholar
• Martínez Martín FJ. Calcium channel-blockers for managing metabolic syndrome-associated hypertension. Trials with manidipine. Nefrologia27(Suppl. 6), 26–35 (2007).
   PubMed Web of Science ®Google Scholar
• Hansson L, Hedner T, Dahlöf B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press.1(2), 113–119 (1992).
   PubMedGoogle Scholar
• McInnes GT. Antihypertensive drugs in combination: additive or greater than additive? J. Hum. Hypertens.21(12), 914–916 (2007).
   PubMed Web of Science ®Google Scholar
• Gojanovic B, Feihl F, Liaudet L, Waeber B. Concomitant calcium entry blockade and inhibition of the renin–angiotensin system: a rational and effective means for treating hypertension. J. Renin Angiotensin Aldosterone Syst.9(1), 1–9 (2008).
   PubMed Web of Science ®Google Scholar
• Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr. Cardiol. Rep.4(6), 479–482 (2002).
   PubMedGoogle Scholar
• Tuomilehto J, Rastenyte D, Birkenhäger WH et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N. Engl. J. Med.340(9), 677–684 (1999).
   PubMed Web of Science ®Google Scholar
• Robles NR, Ocón J, Gómez CF et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren. Fail.27(1), 73–80 (2005).
   PubMed Web of Science ®Google Scholar
• Agodoa LY, Appel L, Bakris GL et al; African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA285(21), 2719–2728 (2001).
   PubMed Web of Science ®Google Scholar
• Sakamaki Y, Sasamura H, Ikeda S et al. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan. Hypertens. Res.29(5), 333–338 (2006).
   PubMed Web of Science ®Google Scholar
• Fogari R, Mugellini A, Zoppi A et al. Effect of successful hypertension control by manidipine or lisinopril on albuminuria and left ventricular mass in diabetic hypertensive patients with microalbuminuria. Eur. J. Clin. Pharmacol.61(7), 483–490 (2005).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ. Res.100(3), 342–353 (2007).
   PubMed Web of Science ®Google Scholar
• Roca-Cusachs A, Schmieder RE, Triposkiadis F et al. MORE Study Group. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. J. Hypertens.26(4), 813–818 (2008).
   PubMed Web of Science ®Google Scholar
• Coca A. Manidipine plus delapril in patients with Type 2 diabetes and hypertension: reducing cardiovascular risk and end-organ damage. Expert Rev. Cardiovasc. Ther.5(2), 147–159 (2007).
   PubMedGoogle Scholar
• Mugellini A, Preti P, Zoppi A et al. Effect of delapril-manidipine combination vs irbesartan-hydrochlorothiazide combination on fibrinolytic function in hypertensive patients with type II diabetes mellitus. J. Hum. Hypertens.18(10), 687–691 (2004).
   PubMed Web of Science ®Google Scholar
• Fogari R, Derosa G, Zoppi A et al. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with Type 2 diabetes mellitus. Hypertens. Res.31(1), 43–50 (2008).
   PubMed Web of Science ®Google Scholar
• Otero ML, Claros NM; Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and Type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study. Clin. Ther.27(2), 166–173 (2005).
   PubMed Web of Science ®Google Scholar
• Zanchetti A, Omboni S, La Commare P, De Cesaris R, Palatini P. Efficacy, tolerability, and impact on quality of life of long-term treatment with manidipine or amlodipine in patients with essential hypertension. J. Cardiovasc. Pharmacol.38(4), 642–650 (2001).
   PubMed Web of Science ®Google Scholar
• Payeras AC, Sladek K, Lembo G, Alberici M. Antihypertensive efficacy and safety of manidipine versus amlodipine in elderly subjects with isolated systolic hype rtension: MAISH study. Clin. Drug Investig.27(9), 623–632 (2007).
   PubMed Web of Science ®Google Scholar
• Mulè G, Nardi E, Cottone S et al. Relationship of metabolic syndrome with pulse pressure in patients with essential hypertension. Am. J. Hypertens.20(2), 197–203 (2007).
   PubMed Web of Science ®Google Scholar
• Mazza A, Zamboni S, Tikhonoff V et al. Pulse hypertension: a new component of the metabolic syndrome in elderly women? J. Hum. Hypertens.21(12), 934–941 (2007).
   PubMed Web of Science ®Google Scholar
• Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am. J. Cardiovasc. Drugs7(6), 413–422 (2007).
   PubMed Web of Science ®Google Scholar
• Peng RD, Dominici F, Zeger SL. Reproducible epidemiologic research. Am. J. Epidemiol.163(9), 783–789 (2006).
   PubMed Web of Science ®Google Scholar
• Bellinghieri G, Mazzaglia G, Savica V, Santoro D. Effects of manidipine and nifedipine on blood pressure and renal function in patients with chronic renal failure: a multicenter randomized controlled trial. Ren. Fail.25(5), 6818–6819 (2003).
   Google Scholar